What changed today in Metabolic: 20 trial updates, 9 new studies

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

Source file

1. [1]
   New trial registered: Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Sep 29, 2026

2. [2]
   New trial registered: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver… (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Sep 29, 2026

3. [3]
   New trial registered: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished… (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Sep 29, 2026

4. [4]
   New trial registered: Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by… (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Sep 29, 2026

5. [5]
   New trial registered: SEMAFORCRANIO (SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in…) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Sep 28, 2026

6. [6]
   New trial registered: A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Sep 28, 2026

7. [7]
   New trial registered: TIRZE-PAP (Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative…) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Sep 28, 2026

8. [8]
   New trial registered: Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Sep 28, 2026

9. [9]
   New trial registered: TELWA (Probiotics in Obese Patients Treated With GLP-1 Receptor Agonists) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Sep 28, 2026

10. [10]
    New trial registered: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or… (opens the source in a new tab)

    Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Sep 28, 2026

11. [11]
    New Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says (opens the source in a new tab)

    News reportingMedPage TodaySep 30, 2026Industry coverage — headline and link only

12. [12]
    STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial (opens the source in a new tab)

    News reportingSTATSep 30, 2026Industry coverage — headline and link only

13. [13]
    Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds (opens the source in a new tab)

    News reportingPharmacy TimesSep 30, 2026Industry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.